Literature DB >> 21536506

Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Siver Andreas Moestue1, Olav Engebraaten, Ingrid Susann Gribbestad.   

Abstract

Despite huge efforts in development of drugs targeting oncogenic signalling, the number of such drugs entering clinical practice to date remains limited. Rational use of biomarkers for drug candidate selection and early monitoring of response to therapy may accelerate this process. Magnetic resonance spectroscopy (MRS) can be used to assess metabolic effects of drug treatment both in vivo and in vitro, and technological advances are continuously increasing the utility of this non-invasive method. In this review, we summarise the use of MRS for monitoring the effect of targeted anticancer drugs, and discuss the potential role of MRS in the context of personalised cancer treatment.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21536506      PMCID： PMC5528296          DOI： 10.1016/j.molonc.2011.04.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  134 in total

1.  Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells.

Authors:  M L Anthony; M Zhao; K M Brindle
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

2.  p53 regulates mitochondrial respiration.

Authors:  Satoaki Matoba; Ju-Gyeong Kang; Willmar D Patino; Andrew Wragg; Manfred Boehm; Oksana Gavrilova; Paula J Hurley; Fred Bunz; Paul M Hwang
Journal:  Science       Date:  2006-05-25       Impact factor: 47.728

Review 3.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

4.  Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.

Authors:  Dinesh Singh; Ajit K Banerji; Bilikere S Dwarakanath; Rajendra P Tripathi; Jaganath P Gupta; T Lazar Mathew; Turuga Ravindranath; Viney Jain
Journal:  Strahlenther Onkol       Date:  2005-08       Impact factor: 3.621

5.  Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells.

Authors:  Matthew Milkevitch; Hyunsuk Shim; Ulrich Pilatus; Stephen Pickup; Janna P Wehrle; Dvorit Samid; Harish Poptani; Jerry D Glickson; Edward J Delikatny
Journal:  Biochim Biophys Acta       Date:  2005-02-24

6.  Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.

Authors:  David L Schwartz; James A Bankson; Robert Lemos; Stephen Y Lai; Arun K Thittai; Yi He; Galen Hostetter; Michael J Demeure; Daniel D Von Hoff; Garth Powis
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

7.  18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

Authors:  Kristin McLarty; Aisha Fasih; Deborah A Scollard; Susan J Done; Douglass C Vines; David E Green; Danny L Costantini; Raymond M Reilly
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

8.  Therapeutic target metabolism observed using hyperpolarized 15N choline.

Authors:  Cristina Gabellieri; Steven Reynolds; Arnon Lavie; Geoffrey S Payne; Martin O Leach; Thomas R Eykyn
Journal:  J Am Chem Soc       Date:  2008-03-18       Impact factor: 15.419

9.  Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging.

Authors:  Kayvan R Keshari; David M Wilson; Albert P Chen; Robert Bok; Peder E Z Larson; Simon Hu; Mark Van Criekinge; Jeffrey M Macdonald; Daniel B Vigneron; John Kurhanewicz
Journal:  J Am Chem Soc       Date:  2009-12-09       Impact factor: 15.419

Review 10.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531
View more
  5 in total

Review 1.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

Review 2.  Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.

Authors:  Natalie J Serkova; S Gail Eckhardt
Journal:  Front Oncol       Date:  2016-07-15       Impact factor: 6.244

Review 3.  Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

Authors:  Debra H Josephs; Debashis Sarker
Journal:  Transl Oncogenomics       Date:  2016-02-21

4.  Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.

Authors:  Siver A Moestue; Cornelia G Dam; Saurabh S Gorad; Alexandr Kristian; Anna Bofin; Gunhild M Mælandsmo; Olav Engebråten; Ingrid S Gribbestad; Geir Bjørkøy
Journal:  Breast Cancer Res       Date:  2013-02-28       Impact factor: 6.466

5.  Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Authors:  Nada M S Al-Saffar; Helen Troy; Anne-Christine Wong Te Fong; Roberta Paravati; L Elizabeth Jackson; Sharon Gowan; Jessica K R Boult; Simon P Robinson; Suzanne A Eccles; Timothy A Yap; Martin O Leach; Yuen-Li Chung
Journal:  Br J Cancer       Date:  2018-10-31       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.